Explore 3 Stock Ideas & Industry Insights Download Free Report

Vitrafy Life Sciences Ltd

Company price
2.45 AUD -0.02 ( 0.81%)
Last update at 2026-11-06T05:10:00Z
VOLUME
10
Market Cap
186.80M

Momentum Score

…

Vitrafy Life Sciences Limited engages in the research, development, and commercialization of cryopreservation solutions in Australia. It offers cryopreservation medical devices, including freezers, thawers, and packaging solutions. The company also provides the LifeChain software platform, which controls, trace, tracks, and monitors quality of cryopreserved biomaterials, as well as the Guardion, non-medical hardware device. Its cryopreservation technology is used various applications, such as blood platelets, cell and gene therapies, and aquaculture and bovine breeding programs. Vitrafy Life Sciences Limited was incorporated in 2017 and is based in Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.45
Low
2.45
High
52 Week Price Range
1.28
Low
4.66
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Vitrafy Life Sciences Ltd is an Australia-listed company in the life sciences sector; public disclosures are limited about its specific operations. Long-term growth drivers may include successful development of any underlying technologies or products, regulatory approvals, and commercial partnerships, and investors may find exposure to potential biotechnology upside and sector diversification.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.47
Dividend Yield
-
Revenue TTM
0.21M
Revenue Per Share
0.00
Gross Profit TTM
-8.46M
Debt / Equity
-
ROE
-46.29%
Net Debt
-
ROCE
-49.33%
Diluted EPS TTM
-0.25

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -16.17M -32.71M -10.43M -7.81M -7.66M
Net income -16.17M -32.71M -10.43M -7.81M -7.66M
Selling general administrative 16.14M 7.34M 2.68M 1.84M 3.63M
Gross profit 0.17M 0.07M 0.04M 0.03M -
Reconciled depreciation 0.12M 0.15M - - -
Operating income -20.44M -16.57M -10.67M -9.16M -6.44M
Interest expense 0.00M 6.49M 10.43M 4.99M 2.73M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.80M 0.77M - - -
Net interest income 0.78M -5.72M -10.43M -4.99M -2.73M
Total revenue 0.17M 0.07M 0.04M 0.03M -
Total other income expense net 3.49M -10.49M 10.68M 6.34M 1.51M
Net income from continuing ops -16.17M -32.71M -10.43M -7.81M -7.66M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 43.21M 31.84M 41.33M 0.00M 0.00M
Other current assets - 0.98M 0.38M - -
Total liab 2.10M 3.08M 1.34M 0.00M 0.00M
Total stockholder equity 41.11M 28.77M 39.99M 0.00M 0.00M
Capital stock 117.66M 89.69M 86.90M - -
Retained earnings -79.54M -63.37M -47.42M - -
Cash 26.10M 19.52M 37.97M - -
Total current liabilities 1.78M 2.72M 0.85M 0.00M 0.00M
Total current assets 42.38M 31.25M 40.59M 0.00M 0.00M
Short term investments 15.07M 10.07M - - -
Net receivables 0.11M 0.06M - - -
Accounts payable 1.27M 0.56M 0.40M - -
Non currrent assets other - - -0.00M - -
Non current assets total 0.84M 0.59M 0.74M 0.00M 0.00M
Capital lease obligations 0.30M 0.39M 0.47M - -
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments -5.00M -10.07M -0.01M -0.09M -0.49M
Net borrowings - - 12.00M 5.91M -
Total cash from financing activities 27.88M 31.99M 11.50M 5.80M -0.06M
Net income -16.17M -32.71M -6.76M -7.81M -7.66M
Change in cash 6.57M 13.11M 4.69M 0.76M -6.42M
Begin period cash flow 19.52M 6.41M 1.72M 0.96M 7.38M
End period cash flow 26.10M 19.52M 6.41M 1.72M 0.96M
Issuance of capital stock 30.00M 35.32M 0.27M 0.09M -
Sale purchase of stock -2.03M -3.25M - - -
Capital expenditures 0.54M 0.00M 0.01M 0.09M 0.49M
Free cash flow -16.31M -8.80M -6.80M -5.05M -6.36M

Peer Comparison*

Sector: Technology Industry: Software - Infrastructure

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
VFY
Vitrafy Life Sciences Ltd
-0.02
0.81%
2.45 - - 893.81 4.64 887.51
XYZ
Block, Inc
-2.22
1.78%
122.66 111.51 15.77 2.89 2.22 1.63
MP1
Megaport Ltd
-0.69
3.89%
17.06 - 138.89 13.81 4.10 12.09
CCL
Cuscal Ltd
-0.07
1.17%
5.89 26.77 20.28 1.97 2.73 5.15
AXQ
Aura Consolidated Group, Inc.
0.02
0.58%
3.48 - - 3.78 - 5.49

Profile*

Vitrafy Life Sciences Ltd

Vitrafy Life Sciences Limited engages in the research, development, and commercialization of cryopreservation solutions in Australia. It offers cryopreservation medical devices, including freezers, thawers, and packaging solutions. The company also provides the LifeChain software platform, which controls, trace, tracks, and monitors quality of cryopreserved biomaterials, as well as the Guardion, non-medical hardware device. Its cryopreservation technology is used various applications, such as blood platelets, cell and gene therapies, and aquaculture and bovine breeding programs. Vitrafy Life Sciences Limited was incorporated in 2017 and is based in Melbourne, Australia.

385 Bourke Street, Melbourne, VIC, Australia, 3000

61 3 9692 7222

Name Title Year Born
Mr. Brenton Michael Leslie Owens Co-Founder, MD, CEO & Executive Director NA
Mr. Simon Thomas Martin Chief Financial Officer NA
Mr. Michael Sapountzis AGIA, B.Com., L.L.B., M.A.I.C.D. Company Secretary NA
Dr. Heather Pidcoke Chief Science Officer NA
Mr. Timothy P. Costello EVP& Chief Commercial Officer NA
Mr. Timothy P. Costello EVP & Chief Commercial Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…